pioneering next generation approaches to cure neurological conditions.
LATEST NEWS
Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson’s Disease
Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the first patient has been dosed in its Phase 1 REPLACE™ clinical trial of RNDP-001 for the treatment of moderate to moderate-severe idiopathic Parkinson’s disease…
meet kenai therapeutics
We are a clinical-stage biotechnology company advancing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines for the treatment of neurological conditions. Our aim is to deliver disease-modifying and potentially curative treatments that go beyond symptom management to reverse the impact of neurodegeneration – with the goal of restoring quality of life.